Alastair S. Ritchie
London, ENG WC1V6LJ, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications
Adapting the design of the ongoing RAMPART trial in response to external evidence: An example for trials which take many years to run and report.
Journal: Contemporary clinical trials communications
Published: October 16, 2023
External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 25, 2022
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).
Journal: International journal of cancer
Published: December 10, 2021
RAMPART: A model for a regulatory-ready academic-led phase III trial in the adjuvant renal cell carcinoma setting.
Journal: Contemporary clinical trials
Published: March 18, 2021
RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse.
Journal: Contemporary clinical trials
Published: March 18, 2021
Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 14, 2020
Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992-2003.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: February 19, 2020
Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: September 28, 2019
Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer.
Journal: European urology
Published: April 16, 2019
What Survival Benefits are Needed to Make Adjuvant Sorafenib Worthwhile After Resection of Intermediate- or High-Risk Renal Cell Carcinoma? Clinical Investigators' Preferences in the SORCE Trial.
Journal: Kidney cancer (Clifton, Va.)
Published: February 12, 2019
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.
Journal: Lancet (London, England)
Published: September 18, 2018
Last Updated: 09/26/2026